Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors
|
|
- Debra Stephens
- 6 years ago
- Views:
Transcription
1 REPRODUCTIVE SURGERY Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors Yoav Yinon, M.D., Mario E. Beiner, M.D., Walter H. Gotlieb, M.D., Ph.D., Yaacov Korach, M.D., Tamar Perri, M.D., and Gilad Ben-Baruch, M.D. Division of Gynecological Oncology, Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel- Hashomer, Tel-Aviv University, Israel Objective: To compare recurrence rates and fertility outcomes of patients with borderline ovarian tumors (BOTs) who underwent unilateral salpingo-oophorectomy with those of patients who underwent cystectomy only. Design: Retrospective study. Setting: Gynecologic oncology department of a tertiary center. Patient(s): Sixty-two patients with BOTs who underwent fertility-preserving surgery. Intervention(s): Unilateral salpingo-oophorectomy (USO, n 40) or cystectomy only (n 22). Main Outcome Measure(s): Tumor recurrence rate, incidence of pregnancy. Result(s): All 62 patients were alive with no clinical evidence of disease after a mean follow-up of 88 months. There was no statistically significant difference in mean tumor recurrence rates between patients who had undergone cystectomy only and those who had undergone USO (22.7% and 27.5%, respectively). In the cystectomy-treated group, the disease-free interval was shortened (23.6 compared with 41 mo), but the difference was not significant. However, the mean follow-up period for the cystectomy group was significantly shorter than for the USO group. Of the 62 patients, 25 (40.3%) attained 38 pregnancies, resulting in 35 deliveries. Conclusion(s): Our results support previous findings that conservative surgery is an acceptable option for women with BOTs who wish to preserve fertility. Cystectomy, like oophorectomy, appears to be an adequate treatment, provided that the patient is willing to undergo careful and prolonged follow-up. (Fertil Steril 2007;88: by American Society for Reproductive Medicine.) Key Words: Borderline ovarian tumors, conservative treatment, fertility-preserving surgery Borderline tumors of the ovary, also known as low malignant potential tumors, account for 10% 15% of all ovarian tumors. Studies have consistently demonstrated the favorable prognosis of these tumors, with an overall 10-year survival rate of 83% 91% (1, 2). Although these tumors are usually benign, they can present as a metastatic disease and can recur as long as 10 years after the primary diagnosis. Recurrence in the form of invasive carcinoma is rare (3). Borderline ovarian tumors (BOTs) often occur in reproductiveage women. Because of their generally benign behavior, their management has become more conservative, allowing women to maintain fertility (4 6). Fertility-preserving treatments include procedures in which the uterus and at least some functional ovarian tissue remain, enabling pregnancy Received May 13, 2006; revised and accepted November 21, Reprint requests: Yoav Yinon, M.D., or Gilad Ben-Baruch, M.D., Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel (FAX: ; yinony@barak-online.net or benbaruc@post.tau.ac.il) achievement even though the loss of a considerable part of the oocyte reserve may reduce fertility (4, 7). Previous studies have indicated the safety of conservative surgery with unilateral salpingo-oophorectomy (USO) or cystectomy for patients with stage I BOTs (8, 9). However, only limited data are available with regard to the clinical outcome and fertility after cystectomy only. The aim of this study was to compare the outcome of patients treated by cystectomy only with that of patients treated by USO. MATERIALS AND METHODS This retrospective study was based on the collected data, including inpatient and outpatient records, surgical notes, and pathology reports, of all consecutive patients with BOTs who were treated in our center between 1979 and 2004 (n 158). Our study group comprised 62 patients who had undergone fertility-preserving surgery, defined as any procedure in which the uterus and at least some ovarian tissue were left intact. Some of these patients were included in our reports published elsewhere (6, 10) /07/$32.00 Fertility and Sterility Vol. 88, No. 2, August 2007 doi: /j.fertnstert Copyright 2007 American Society for Reproductive Medicine, Published by Elsevier Inc. 479
2 Two pathologists had reviewed all of the original histology slides and confirmed the diagnosis of BOT, defined as an ovarian tumor with stratification of the epithelial lining, formation of microscopic papillary projections, presence of nuclear atypia, and absence of frank stromal invasion (11, 12). Stage of disease had been defined according to the 1988 International Federation of Gynecology and Obstetrics criteria, based on surgical notes and pathology reports. Followup had included physical examination, pelvic sonography, and CA-125 blood test every 3 months for 3 years after the operation and twice yearly thereafter. If a suspicious ovarian mass was found, the patient had undergone another operation. The mean tumor recurrence rate and mean incidence of pregnancy in women who had undergone only cystectomy were compared with those in women who had undergone USO. Student s t-test and the 2 test were used for statistical analysis of the results. P values of.05 were considered significant. The study was approved by the ethics committee of the Chaim Sheba Medical Center. RESULTS Of the 62 patients with BOTs who had undergone conservative surgery, 33 had cystectomy and 29 had USO. The mean age at diagnosis for the total group was 28 years (range 13 44). Tumors were serous in 38 cases (61.3%) and mucinous in 24 (38.7%). Two patients had a serous BOT with micropapillary pattern. There was no significant difference in the median size of the tumor between the patients who initially underwent cystectomy and patients who initially underwent USO (10 cm vs. 9 cm respectively, P.77). In 14 of the 29 patients in the USO group, the procedure had included surgical staging. In 2 of these patients, this was performed within 3 months after the primary surgery FIGURE 1 Primary surgical procedure in women undergoing fertility-sparing surgery for borderline ovarian tumor. TABLE 1 Characteristics of women undergoing cystectomy or unilateral salpingooophorectomy for borderline ovarian tumor. Parameter USO (%) (n 40) Cystectomy only (%) (n 22) P value Mean age (y) Histology Serous, n (%) 21 (52.5) 17 (77).056 Mucinous, 19 (47.5) 5 (23).056 n (%) Surgical staging, 25 (63) 1 (5) n (%) Apparent stage I, n (%) 36 (90) 21 (95).46 Note: All P values are statistically nonsignificant. (Fig. 1). Twelve of the patients in the cystectomy-only group had undergone reoperation within 3 months; of these, 9 had undergone USO and surgical staging, 2 had USO only, and 1 had surgical staging that did not include ovarian biopsy (Fig. 1). None of the reoperated patients demonstrated evidence of persistent disease. We defined the extent of surgical treatment on the basis of both the primary surgical procedure and reoperation within 3 months after the primary surgery. Accordingly, the patients were divided into two groups. As shown in Table 1, there were 22 women in the cystectomy-only group and 40 in the USO group. There were no differences between the two groups in age at diagnosis or in the numbers of women whose tumors were serous in nature. Twenty-one patients (95.4%) in the cystectomy group had apparent stage I disease, compared with 36 patients (90%) in the USO group (P.46). The only surgically staged patient in the cystectomy group was found to have stage IIIa disease. Of the 25 patients in the USO group who were staged, one was diagnosed with stage IIc disease and three with stage III disease (one with stage IIIb and two with stage IIIc). Within a mean period of 36 months (range 7 81 mo), 16 (25.8%) of the 62 women developed a local recurrence (Table 2). The cystectomy-only group did not differ significantly from the USO group with regard to the incidence of recurrence, nor in the mean interval between diagnosis and recurrence. The mean follow-up period for the cystectomy group was significantly shorter than for the USO group (Table 2). Comparison of the patients with serous tumors (17 women in the cystectomy-only group and 21 in the USO group; Table 3) revealed no significant difference in their mean recurrence rates. As shown, the mean interval between di- 480 Yinon et al. Conservative treatment of borderline tumors Vol. 88, No. 2, August 2007
3 TABLE 2 Clinical outcome of women undergoing cystectomy or unilateral salpingo-oophorectomy for borderline ovarian tumor. Parameter USO (%) (n 40) Cystectomy (%) (n 22) P value Reoperation (%) 15 (37.5) 6 (27) Recurrence (%) 11 (27.5) 5 (22.7).8 (NS) Mean interval to recurrence (range), mo 41 (9 81) 23.6 (7 41).2 (NS) No. of women pregnant (%) 19 (47.5) 6 (22.7) No. of pregnancies 31 b 7 a No. of deliveries 28 7 Mean follow up (range), mo 101 (6 30) 65 (6 180).05 Note: NS not significant. a Two after IVF treatment. b Three after IVF treatment. agnosis and recurrence in these patients was shorter, though not significantly, in the cystectomy-only group than in the patients with USO. In the cystectomy-only group, six patients had undergone reoperation because of suspected local recurrence, and in five of them the diagnosis of recurrent borderline tumor was confirmed. All of the recurrences in this treatment group were in patients with serous ovarian tumors (four ipsilateral and one contralateral). Three of these patients underwent salpingo-oophorectomy of the involved ovary, and two underwent a second cystectomy. One patient in this group, after undergoing cystectomy for recurrent tumor in the contralateral ovary, had a second recurrence in the contralateral ovary 3 years after the first recurrence. In view of her desire to preserve fertility, she underwent another cystectomy; 2 months later, however, in view of evidence of borderline tumor in the capsule of the ovary on final pathologic report, she opted to have the remaining ovary removed. Notably, all recurrences in this group were of borderline malignancy. In the USO group, 15 patients had undergone reoperation because of suspected local recurrence, and in 11 of them the diagnosis was confirmed. Nine of the 11 recurrences were in patients with serous tumors. Six of the 11 patients wished to preserve fertility and underwent cystectomy, 2 patients underwent salpingo-oophorectomy, and 3 patients underwent salpingo-oophorectomy and hysterectomy. Pathologic findings were borderline in 10 patients, and in one patient histopathological examination revealed endometrioid ovarian carcinoma. This patient initially underwent LSO staging because of left mucinous BOT. Nine months later, she was reoperated on because of a contralateral ovarian mass and underwent RSO. At this time, the histopathological diagnosis was endometrioid ovarian carcinoma. She was treated with chemotherapy and underwent total abdominal TABLE 3 Clinical outcome of women undergoing cystectomy or USO for serous borderline ovarian tumor. Parameter USO (%) (n 21) Cystectomy (%) (n 17) P values Reoperation (%) 11 (52) 6 (35) Recurrence (%) 9 (43) 5 (29).4 Mean interval to recurrence, mo No. of women pregnant 8 5 No. of pregnancies 11 7 No. of deliveries 8 7 Mean follow-up (mo) Note: All P values are statistically not significant. Fertility and Sterility 481
4 hysterectomy (TAH) a few months later because of endometrial carcinoma. She is alive and free of disease 14 years after her initial diagnosis. All patients with recurrences were alive and free of disease at a mean follow-up of 69 months from diagnosis of recurrence. After treatment of the borderline tumor, 38 pregnancies were achieved in 25 women, resulting in 35 deliveries (Table 2). The mean time between operation and pregnancy was 42 months (range, mo). In the cystectomy-only group, six women had seven pregnancies (two of them achieved after IVF treatment), resulting in seven deliveries. In the USO group, 19 women had 31 pregnancies (three achieved after IVF treatment), resulting in 28 deliveries. One of these patients had been diagnosed with right-sided BOT during IVF treatments for unexplained infertility. Cystectomy together with complete staging had disclosed stage IIIa serous BOT. After recurrence 6 months later, she had undergone another cystectomy. She subsequently conceived by IVF, delivering her first child 18 months after the primary surgery and another child after IVF treatment 2 years later. Four months after her second delivery, the left ovary developed a second recurrence, and she underwent USO. Currently ( 2 y after the last recurrence), she shows no evidence of disease. DISCUSSION Patients with BOTs tend to be younger than women with invasive ovarian cancer (3, 8), and many of them wish to preserve their fertility. The usual standard management has traditionally been total hysterectomy with bilateral adnexectomy, but conservative treatment of borderline tumors is receiving increasing consideration as an acceptable option. Ovarian cystectomy may provide a better chance of preserving fertility than adnexectomy because in the former procedure, less ovarian tissue is removed. The risk is that some malignant cells inadvertently may be left behind. Although the question of fertility-sparing surgery has been addressed in many studies, only limited published data are available on the safety and outcome of treatment by cystectomy only. We compared the tumor recurrence rates and incidence of pregnancy in 22 women who had undergone only cystectomy with those in 40 women who had undergone USO. There was no significant difference between the two groups in mean recurrence rates (22.7% and 27.5%, respectively; Table 2), and this finding did not change when analyzed according to the histological type of the tumor (serous tumors only; Table 3). The time lapse between diagnosis and recurrence was shorter, though not significantly, in the cystectomy-only group than in the USO group (23.6 and 41 mo, respectively). Accumulating evidence indicates that unilateral oophorectomy provides a safe therapeutic alternative to BOTs in women wishing to preserve fertility (8, 9, 13). In a study of 339 women treated for BOTs, Zanetta et al. (14) reported that despite a higher mean recurrence rate for women undergoing fertility-preserving surgery (35/189 cases, 18.5%) than for women undergoing hysterectomy and bilateral salpingo-oophorectomy (7/150 cases, 4.7%), all but one woman (in whom conservative surgery was followed by progression to carcinoma), were salvaged. Camatte et al. (15) reported recurrence in only 2/17 women with stage II or stage III BOT treated with fertility-preserving surgery, with no deaths at a median follow-up of 60 months. In a recent study by Fauvet et al. (16), in which 162 of 360 women with BOTs underwent conservative surgery, the mean recurrence rate was significantly higher in the conservatively treated group than in the group who underwent radical surgery (16.6% compared with 4.5%). However, in no case did the carcinoma recur during the study period, and none of the conservatively treated women died of the disease. A lower mean recurrence rate after conservative surgery (6.5%) was recently reported, but it was still higher than that obtained after radical surgery (17). All of the above studies thus demonstrated that although conservative surgery is associated with a higher incidence of recurrence, in most cases surgical salvage is possible and therefore recurrence does not affect survival (4, 14 17). The findings of the present study indicate that cystectomy, like oophorectomy, appears to be a satisfactory therapy in women who are willing to undergo careful and prolonged follow-up examination. We are aware of the fact that the lack of difference in recurrence rates between our two groups may be attributable, at least in part, to the small sample size and the shorter follow-up period of the cystectomy group compared with those of the USO group (a discrepancy that arises from the relatively recent introduction of cystectomy as an acceptable treatment for BOT). Another limitation of this study is the imbalance between the cystectomy-only and the USO groups with regard to histology. However, when we restricted our analysis to patients with serous tumors only, similar results were obtained. Lim-Tan et al. (9) reported on a series of ovarian cystectomies for serous borderline tumors. Follow-up evaluations of their 35 patients demonstrated that despite four cases of tumor recurrence, all of the women were alive and evidently free of disease 3 to 18 years after the initial surgery. However, within weeks to months after the initial procedure, many of these patients had undergone extension of their surgical treatment and therefore did not fit our definition of cystectomy-only treatment (Table 4). In a prospective Gynaecologic Oncology Group study (8), seven patients underwent ovarian cystectomy with subsequent surgical reexploration to complete the staging procedure. No residual tumors were detectable in any of the cystectomized ovaries. Zanetta et al. (14) reported nine recurrences in 50 women (18%) with stage I borderline tumors treated by cystectomy only (Table 4). In contrast to our findings are those of Morice et al. (5) in their study of 44 patients who were treated conservatively, 482 Yinon et al. Conservative treatment of borderline tumors Vol. 88, No. 2, August 2007
5 TABLE 4 Summary of published reports on women with borderline tumors treated by cystectomy. Reference No. of patients Mean follow-up (mo) Clinical outcome Interval to recurrence (mo) Recurrence rate (%) Lim-Tan et al. (9) 35 a 90 NED NS 11.4 Morice et al. (5) NED NS 36.3 Zanetta et al. (14) NED Present study NED Note: NS not stated; NED no evidence of disease at last follow-up. a Twenty-one patients underwent re-operation, thus only 14 patients fit our definition of cystectomy-only treatment. 11 with cystectomy and 33 with USO. Recurrence rates were 36.3% and 15.1%, respectively. The investigators concluded that the ideal conservative treatment is USO and that cystectomy should be reserved for patients who have previously undergone adnexectomy but who subsequently require treatment for a recurrent borderline tumor and wish to preserve fertility. Our findings suggested, however, that the procedures are equally safe. The apparent difference in the findings may be attributable to the smaller study group of Morice et al. (5) (Table 4). A diagnosis of BOT is often made after laparoscopic cystectomy for an apparently benign ovarian cyst. Our data suggested that in young women with an incidental diagnosis of serous- or endocervical-type BOT, reoperation can safely be avoided and careful follow-up instituted instead. Of our 62 patients, 33 had undergone cystectomy as their initial operation, and in 11 of them, the surgical treatment was expanded to salpingo-oophorectomy within 3 months. Retrospectively, in view of the results, this second surgery was probably not advisable. Our data also confirm that cystectomy offers a safe treatment for patients with recurrent borderline tumor and a history of adnexectomy who wish to preserve fertility. Even if cystectomy increases the risk of recurrence, the recurrent disease is amenable to surgical treatment, and patient survival is not affected by this approach (5). In our study, 25 women had achieved 38 pregnancies after treatment, resulting in 35 deliveries. Five of these pregnancies were achieved as a result of IVF. Reported spontaneous fertility rates after conservative treatment for BOT vary between 32% and 65% (16, 18). Seracchioli et al. (19) described 10 patients who attempted pregnancy of 19 women who had undergone conservative surgery for BOTs. Six of them conceived spontaneously and delivered at term. The disease did not affect the gestation or the follow-up period after the pregnancy. Fauvet et al. described 65 women who attempted to conceive after conservative treatment for BOT (16). Of the 30 pregnancies attained, 27 were spontaneous and 3 followed ovarian stimulation or IVF. With regard to the rate of tumor recurrence or mean time to recurrence, women who conceived did not differ from women who did not conceive (16). We described elsewhere 43 patients who were treated conservatively for BOTs (10). Thereafter, 19 patients delivered 25 healthy children. Seven of these patients were treated with IVF. Of these 7 women, 4 experienced recurrence of BOT, 2 before and 2 after IVF treatments. Our data therefore support the feasibility of fertility treatments and pregnancy for women treated for BOT, because even if disease recurs, it is almost always treatable. An additional question is whether reoperation should be performed to remove the remaining ovary when fertility is no longer desired. To date, no standard practice has been accepted. It appears, however, that because recurrent diseases (borderline type in most cases) can easily be cured by removal, it would probably be safe to consider that systematic removal of the spared ovary is not mandatory (20). Our current policy does not include systematic removal of the spared ovary, provided that the patient is willing to undergo a prolonged follow-up. In conclusion, our results confirm that conservative surgery is an acceptable option for women with BOTs who wish to preserve fertility. Cystectomy, like oophorectomy, appears to be an adequate treatment, provided that the patient is willing to undergo careful and prolonged follow-up. REFERENCES 1. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981;12: Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65: Crispens MA. Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 2003;15: Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003;79: Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001;75:92 6. Fertility and Sterility 483
6 6. Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben- Baruch G. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998;82: Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum Reprod Update 1998;4: Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995;13: Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988;72: Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001;92: Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973; 31: Scully RE. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential). Bull Cancer 1982;69: Tasker M, Langley FA. The outlook for women with borderline epithelial tumours of the ovary. Br J Obstet Gynaecol 1985;92; Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001;19: Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. Br J Obstet Gynaecol 2002; 109: Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005;83: Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005;97: Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer 2006;42: Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bagnoli A. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001;76: Morice P, Camatte S, Wicart-Poque F, Atallah D, Rouzier R, Pautier P, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003;9: Yinon et al. Conservative treatment of borderline tumors Vol. 88, No. 2, August 2007
Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 250e254 Original Article Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian
More informationFeasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors
Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors Raffaele Tinelli, M.D., a Mario Malzoni, M.D., a Francesco Cosentino, M.D., a Ciro Perone, M.D., a
More informationSurvival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran
ORIGINAL ARTICLE Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran Katayoun Ziari, Ebrahim Soleymani, and
More informationBorderline Ovarian Tumours. Andreas Obermair Brisbane
Borderline Ovarian Tumours Andreas Obermair Brisbane Definition First described in 1929 Cellular features of malignancy Cellular atypia Mitotic activity No stromal invasion An entity per se??? (or precursor
More informationOutcome and Reproductive Function After Conservative Surgery for Borderline Ovarian Tumors
Outcome and Reproductive Function After Conservative Surgery for Borderline Ovarian Tumors ROBERT T. MORRIS, MD, DAVID M. GERSHENSON, MD, ELVIO G. SILVA, MD, MICHELE FOLLEN, MD, MITCHELL MORRIS, MD, AND
More informationThe impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients ( 40 years old) with borderline ovarian tumors
Fang et al. BMC Cancer (2018) 18:1147 https://doi.org/10.1186/s12885-018-4932-2 RESEARCH ARTICLE Open Access The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients
More informationPredictive value of CA 125 and CA 72-4 in ovarian borderline tumors
Article in press - uncorrected proof Clin Chem Lab Med 2009;47(5):537 542 2009 by Walter de Gruyter Berlin New York. DOI 10.1515/CCLM.2009.134 2009/623 Predictive value of CA 125 and CA 72-4 in ovarian
More informationOriginal contribution
Human Pathology (2012) 43, 747 752 www.elsevier.com/locate/humpath Original contribution The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher
More informationGestione dei tumori borderline iniziali e avanzati nelle donne in età fertile
Gestione dei tumori borderline iniziali e avanzati nelle donne in età fertile Pierandrea De Iaco pierandrea.deiaco@aosp.bo.it SSD ONCOLOGIA GINECOLOGICA AOU SANT ORSOLA-MALPIGHI BOLOGNA Borderline ovarian
More informationC. Poncelet, R. Fauvet, C. Yazbeck, C. Coutant, E. Darai. To cite this version: HAL Id: hal
Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: Multivariate analysis of a french multicentre study C. Poncelet, R. Fauvet, C. Yazbeck, C. Coutant,
More informationA Serous Borderline Tumor of the Fallopian Tube Detected Incidentally
A Serous Borderline Tumor of the Fallopian Tube Detected Incidentally Imrana Tanvir, Ghania Ali, Haseeb Ahmed Khan and Ahmed Nasir Hanifi* Dept. of Histopathology, FMH College of Medicine & Dentistry,
More informationFertility Preservation Is Safe for Serous Borderline Ovarian Tumors
ORIGINAL STUDY Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors Eveline Vancraeynest, MD,* Philippe Moerman, MD, PhD,Þ Karin Leunen, MD, PhD,* Frédéric Amant, MD, PhD,* Patrick Neven,
More informationIMMATURE TERATOMA: SURGICAL TREATMENT
CARAVAGGIO 10-12 MAGGIO 2010 IMMATURE TERATOMA: SURGICAL TREATMENT G. Mangili, E. Garavaglia, C. Sigismondi R VIGANO Dipartimento Materno Infantile, UF Ginecologia Oncologica IRCCS San Raffaele Milano
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationHJOG. Fertility sparing options for women with ovarian neoplasms. Review. Abstract
HJOG An Obstetrics and Gynecology International Journal Review Fertility sparing options for women with ovarian neoplasms Zygouris Dimitrios 1, Panagopoulos Perikles 1, Christodoulaki Chrysi 1, Vrachnis
More informationClear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder and lymph node metastasis
Liu et al. World Journal of Surgical Oncology 2014, 12:51 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationAccuracy of ultrasound subjective pattern recognition for the diagnosis of borderline ovarian tumors
Ultrasound Obstet Gynecol 2007; 29: 489 495 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.4002 Accuracy of ultrasound subjective pattern recognition for the diagnosis
More informationRESEARCH ARTICLE. Usanee Chatchotikawong 1, Irene Ruengkhachorn 1 *, Chairat Leelaphatanadit 1, Nisarat Phithakwatchara 2. Abstract.
RESEARCH ARTICLE 8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors Usanee Chatchotikawong 1, Irene
More informationSEROUS TUMORS. Dr. Jaime Prat. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona
SEROUS TUMORS Dr. Jaime Prat Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Serous Borderline Tumors (SBTs) Somatic genetics Clonality studies have attempted to dilucidate whether
More informationDavid Nunns on behalf of the Gynae Guidelines Group Date:
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Borderline tumours of the ovary management and follow-up Author: Contact Name and Job Title Directorate & Speciality
More informationArticle begins on next page
Pseudopapillary Granulosa Cell Tumor: A Case of This Rare Subtype Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/50622/story/]
More informationSurgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy
Acta Obstetricia et Gynecologica. 2007; 86: 620 626 ORIGINAL ARTICLE Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy ELIN ØDEGAARD
More informationImpact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma
Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of
More informationFERTILITY SPARING IN ENDOMETRIAL CANCER
FERTILITY SPARING IN ENDOMETRIAL CANCER Prof. Dr. Bülent Özçelik Erciyes University Medical Faculty Department of Obstetrics and Gynecology Gynecologic Oncology Unit Endometrial Cancer Most frequent gynecologic
More informationA Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Gynecologic Oncology A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants INES VASCONCELOS,JESSICA OLSCHEWSKI,IOANA BRAICU,JALID
More informationAnnual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
More informationRisk of synchronous endometrial disorders in women with endometrioid borderline tumors of the ovary
Jia et al. Journal of Ovarian Research (2018) 11:30 https://doi.org/10.1186/s13048-018-0405-0 RESEARCH Open Access Risk of synchronous endometrial disorders in women with endometrioid borderline tumors
More informationMalignant Ovarian Germ Cell Tumours: Experience in the National University Hospital of Singapore
657 Malignant Ovarian Germ Cell Tumours: Experience in the National University Hospital of Singapore F K Lim,*MBBS, M Med, MRCOG, B Chanrachakul,**MBBS, S M Chong,***MBBS, FRCPath, FRCPA, S S Ratnam,****MD,
More informationBorderline tumors of the ovary: a separate entity
Borderline tumors of the ovary: a separate entity Authors Key words A.Ph. Makar Excellent prognosis, conservative surgery, adjuvant therapy Summary Borderline ovarian tumors (BOT) account for 10% to 20%
More informationSurgical Management of Endometriosis associated Infertility
Surgical Management of Endometriosis associated Infertility Dr. Ingrid Lok Specialist in Obstetrics and Gynaecology (Honorary Clinical Associate Professor, CUHK) HA commission training 24.2.2014 Endometriosis
More informationINTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for
INTRODUCTION Ovarian cancer is the leading cause of mortality from gynecologic malignancies in the industrialized countries and is responsible for more deaths than both cervical and endometrial tumours.
More informationRecurrence of sex cord tumor with annular tubules in young patient with Peutz-Jeghers syndrome
Slimane et al. 74 CASE REPORT PEER REVIEWED OPEN ACCESS Recurrence of sex cord tumor with annular tubules in young patient with Peutz-Jeghers syndrome Meher Slimane, Selma Gadria, Manel Hadidane, Houyem
More informationImpact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles
1 st SEUD Meeting, 9 May 2015, Paris, France Impact of Ovarian Endometrioma Per Se and Surgery on Ovarian Reserve and Pregnancy Rate in in Vitro Fertilization Cycles ENDOMETRIOSIS ovarian endometrioma
More informationSquamous cell carcinoma arising in a dermoid cyst of the ovary: a case series
DOI: 10.1111/j.1471-0528.2007.01478.x www.blackwellpublishing.com/bjog Gynaecological oncology Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series JL Hurwitz, a A Fenton, a WG
More informationPrognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
J Gynecol Oncol Vol. 20, No. 3:158-163, September 2009 DOI:10.3802/jgo.2009.20.3.158 Original Article Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
More informationHistological pattern of ovarian tumors and their age distribution
Original Article Nepal Med Coll J 2008; 10(2): 81-85 Histological pattern of ovarian s and their age distribution R Jha and S Karki Department of Pathology, TUTH, Maharajgunj, Kathmandu, Nepal Corresponding
More informationAsk the Experts Obstetrics & Gynecology
1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationRole of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters
Naz et al. World Journal of Surgical Oncology (2015) 13:315 DOI 10.1186/s12957-015-0732-1 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Role of peritoneal washing in ovarian malignancies: correlation
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationA Survay on Appendiceal Involvement in Ovarian Mucinous Tumors
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.33 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 199 203 ISSN 2330-4456 A Survay
More informationQUT Digital Repository: This is the author version published as:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author version published as: Bisseling, Karin and Kondalsamy-Chennakesavan, Srinivas and Bekkers, Ruud and Janda, Monika and Obermair, Andreas
More informationManaging infertility when adenomyosis and endometriosis co-exist
Managing infertility when adenomyosis and endometriosis co-exist Jinhua Leng Beijing,China Endometriosis Endometriosis (EM) is a common, benign, ovary hormone-dependent gynecologic disorder which affects
More informationLaparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies
Laparoscopic fertility-sparing staging in unexpected early stage ovarian malignancies Ludovico Muzii, M.D., a Innocenza Palaia, M.D., b Milena Sansone, M.D., b Marco Calcagno, M.D., b Francesco Plotti,
More informationLow-grade serous neoplasia. Robert A. Soslow, MD
Low-grade serous neoplasia Robert A. Soslow, MD soslowr@mskcc.org Outline Orientation Ovarian tumor overview Non serous borderline tumors Serous borderline tumors Clinical summary Morphologic description
More informationCase # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor
Case # 4 Low-Grade Serous Carcinoma (Macropapillary) of the Ovary Arising in an Atypical Proliferative Serous Tumor Robert J Kurman, M.D. Johns Hopkins University School of Medicine Case History A 53 year
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More informationAnnual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
More informationHistopathological Spectrum of Lesions in Fallopian Tube
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. III (January. 2017), PP 75-80 www.iosrjournals.org Histopathological Spectrum of Lesions
More informationFertility Preservation in Female Cancer Patients
Fertility Preservation in Female Cancer Patients Ali AYHAN, MD. Baskent University School of Medicine Department of Obstetrics & Gynecology Division of Gynecologic Oncology Main Goal of Cancer Therapy
More informationPort-Site Metastases After Robotic Surgery for Gynecologic Malignancy
SCIENTIFIC PAPER Port-Site Metastases After Robotic Surgery for Gynecologic Malignancy Noah Rindos, MD, Christine L. Curry, MD, PhD, Rami Tabbarah, MD, Valena Wright, MD ABSTRACT Background and Objectives:
More informationSurgical consideration for future fertility in gynecologic malignancies
Surgical consideration for future fertility in gynecologic malignancies Hyun Hoon Chung, M.D., Ph.D. Department of Obstetrics and Gynecology Seoul National University College of Medicine Conflict of Interest:
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationStage 3 ovarian cancer survival rate
Search Stage 3 ovarian cancer survival rate 19-5-2017 If you've been diagnosed with ovarian cancer, it's natural to wonder about your prognosis. Learn about survival rates, outlook, and more. Take the
More informationStage 3 ovarian cancer survival rate
Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014
More informationShina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya
Comparison of Synchronous Endometrial and Ovarian Cancers versus Primary with Metastasis RESEARCH COMMUNICATION Clinicopathologic Variables and Survival Comparison of Patients with Synchronous Endometrial
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationImplementation of laparoscopic surgery for endometrial cancer: work in progress
FACTS VIEWS VIS OBGYN, 216, 8 (1): - Original paper Implementation of laparoscopic surgery for endometrial cancer: work in progress A.A.S. VAN DEN BOSCH 1, H.J.M.M. MERTENS 2 1 Junior-resident, Zuyderland
More informationClinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years and Older with Gynecologic Disease
International Scholarly Research Network ISRN Obstetrics and Gynecology Volume 2012, Article ID 678201, 4 pages doi:10.5402/2012/678201 Clinical Study Laparoscopic Surgery in Elderly Patients Aged 65 Years
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationImproving treatment strategies in ovarian cancer: Towards individualized patient care van Meurs, H.S.
UvA-DARE (Digital Academic Repository) Improving treatment strategies in ovarian cancer: Towards individualized patient care van Meurs, H.S. Link to publication Citation for published version (APA): van
More informationLAPAROSCOPY and OVARIAN CANCER
LAPAROSCOPY and OVARIAN CANCER J. DAUPLAT Clermont-Ferrand France UNIVERSITÉ D'AUVERGNE CLERMONT 1 1 - PROPHYLACTIC OOPHORECTOMY 2 - DIAGNOSIS 3 - EARLY STAGES : STAGING 4 - ADVANCED STAGES - ASSESSMENT
More informationUnexpected Gynecologic Findings at Laparotomy. Susan A. Davidson, MD University of Colorado, Denver School of Medicine
Unexpected Gynecologic Findings at Laparotomy Susan A. Davidson, MD University of Colorado, Denver School of Medicine Adnexal Mass: Gyn Etiologies Uterine Leiomyomas Pregnancy Malignancy Tubal Pregnancy
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationCase 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst
Gynaecology Case Presentation Organ Imaging 2016 University of Toronto Sarah Johnson 39 year old female Clinical history: Assess right ovarian cyst Clinically diagnosed endometriosis Started fertility
More informationStage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
Original Investigation 33 Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Gökhan Boyraz, Derman Başaran, Mehmet
More informationSafety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours
Jia et al. BMC Cancer (2018) 18:1160 https://doi.org/10.1186/s12885-018-5091-1 RESEARCH ARTICLE Open Access Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian
More informationPrognostic factors in sex cord stromal tumors of the ovary
Research article Prognostic factors in sex cord stromal tumors of the ovary Achraf HADIJI 1, Tarak DAMAK 1, Lamia CHARFI 2, Jamel BEN HASSOUNA 1, Imen OUESLETI 1, Riadh CHARGUI 1, Khaled RAHAL 1. 1 Service
More informationOvarian Cancer during Pregnancy: Clinical and Pregnancy Outcome
J Korean Med Sci 2010; 25: 230-4 ISSN 1011-8934 DOI: 10.3346/jkms.2010.25.2.230 Ovarian Cancer during Pregnancy: Clinical and Pregnancy Outcome The aim of this study is to evaluate the clinical feature
More informationMalignant transformation in benign cystic teratomas, dermoids of the ovary
European JournalofObstetrics& Gynecology andreproductivebiology, 29 (1988) 197-206 197 Elsevier EJO 00716 Malignant transformation in benign cystic teratomas, dermoids of the ovary S. Chadha 1 and A. Schaberg
More informationOriginal Article Transvaginal sonographic characteristics of paraovarian borderline tumor
Int J Clin Exp Med 2015;8(2):2684-2688 www.ijcem.com /ISSN:1940-5901/IJCEM0004662 Original Article Transvaginal sonographic characteristics of paraovarian borderline tumor Fangui Zhao 1, Hao Zhang 2, Yunyun
More informationSignificance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma
ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More informationFocus on... Ovarian cancer. HE4 & ROMA score
Focus on... Ovarian cancer HE4 & ROMA score Ovarian cancer in the world* Accounting for around 4% of all cancers diagnosed in women The estimated World age-standardised incidence rate for the more developed
More informationMalignant Transformation from Endometriosis to Atypical Endometriosis and Finally to Endometrioid Adenocarcinoma within 10 Years
Published online: September 21, 2013 1662 6575/13/0063 0480$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC)
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationBoth type I and type II tumors develop from extraovarian tissue that implants on the ovary. Both for LGSC and HGSC, the fallopian tube appears to be
Recent studies have led to the development of a new paradigm for the pathogenesis and origin of EOC, based on a dualistic model of carcinogenesis that divides EOC into 2 broad categories designated types
More informationA case of extremely rare ovarian tumor: Primary ovarian adenomyoma
Kawasaki Medical Journal 233 A case of extremely rare ovarian tumor: Primary ovarian adenomyoma Shoji KAKU, Takuya MORIYA, Naoki KANOMATA, Tsuyoshi ISHIDA Yangsil CHANG, Norichika USHIODA, Yuichiro NAKAI
More informationHistopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases
Orginal Article Histopathological analysis of neoplastic and non neoplastic lesions of ovary: A study of one hundred cases 2 G Prathima, Srikanth Shastry 2 Consultant Pathologist, Image Diagnostics, Kadapa,
More informationMelanoma-What Every Woman Need to Know about Fertility and Pregnancy
Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.
More informationShould we offer fertility preservation to all patients with severe endometriosis?
Should we offer fertility preservation to all patients with severe endometriosis? Daniel S. Seidman, MD Department of Ob/Gyn, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Endometriosis
More informationNAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationInnovations in fertility preservation for patients with gynecologic cancers
MODERN TRENDS Edward E. Wallach, M.D. Associate Editor Innovations in fertility preservation for patients with gynecologic cancers Wen-Shiung Liou, M.D., a,c O. W. Stephanie Yap, M.D., a John K. Chan,
More informationHysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure
The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,
More informationCase 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno
Case 1 Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno SAMO Interdisciplinary Workshop on Gynecological Tumors Lucern, October
More informationCancer arising from Endometriosis and Its Clinical implications
Cancer arising from Endometriosis and Its Clinical implications 1) Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign
More informationEndometrial Cancer in Thai Women aged 45 years or Younger
RESEARCH COMMUNICATION Endometrial Cancer in Thai Women aged 45 years or Younger Jitti Hanprasertpong 1 *, Suchada Sakolprakraikij 1, Alan Geater 2 Abstract The aim of this retrospective study was to clarify
More informationOvarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center
Ovarian Tumors Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center Case 13yo female with abdominal pain Ultrasound shows huge ovarian mass Surgeon
More informationBorderline tumors. Borderline tumors. Serous borderline tumor are NOT benign. Low grade serous carcinoma: pathogenesis. Serous carcinoma: pathogenesis
Serous borderline tumor are NOT benign Robert A. Soslow, MD Memorial Sloan-Kettering Cancer Center soslowr@mskcc.org Borderline tumors Serous BTs and seromucinous BTs are both histopathologically borderline
More informationIs Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?
e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:
More informationScreening and prevention of ovarian cancer
Chapter 2 Screening and prevention of ovarian cancer Prevention of ovarian carcinoma Oral contraceptive pills Use of oral contraceptive pills (OCPs) has been associated with a significant reduction in
More informationMousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat
6 Mousa Najat kayed &Renad Al-Awamleh Nizar Alkhlaifat P a g e 1 This sheet written based on record 13 on website Cover slide( 95-117 ) No need to go back to slide FALLOPIAN TUBE PATHOLOGY In general fallopian
More informationMucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology
Mucinous Tumors of the Ovary Beirut, Lebanon Anaís Malpica, M.D. Professor Department of Pathology Primary Mucinous Tumors of the Ovary Cystadenoma Borderline (Tumor of Low Malignant Potential/Atypical
More informationRosekeila Simões Nomelini, 1 Taísa Morete da Silva, 1 Beatriz Martins Tavares Murta, 2 and Eddie Fernando Candido Murta 1. 1.
International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 947831, 5 pages doi:10.5402/2012/947831 Clinical Study Parameters of Blood Count and Tumor Markers in Patients with Borderline
More informationOvarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates?
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.133 RESEARCH ARTICLE Ovarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates? A Taner Turan 1, H Levent Keskin
More informationGERM CELL OVARIAN TUMORS: AN ITALIAN EXPERIENCE
I.R.C.C.S SAN RAFFAELE HOSPITAL-MILAN GERM CELL OVARIAN TUMORS: AN ITALIAN EXPERIENCE Dott.ssa Giorgia Mangili Gynecology and Obstetric Department, IRCCS San Raffaele Hospital Milan. 11/06/2010 PATIENTS
More informationORIGINAL ARTICLE CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL
CA-125 AS A SURROGATE MARKER IN A CLINICAL AND HISTOPATHOLOGICAL STUDY OF PELVIC MASS AT A TERTIARY CARE HOSPITAL Madhuri Kulkarni 1, Ambarish Bhandiwad 2, Sunila R 3, Sumangala 4. 1. Professor, Department
More information